Deuterated etifoxine is a deuterated drug which is under development for the treatment of anxiety disorders and mood disorders.

Maxim Group analyst Michael Okunewitch has maintained their bullish stance on ATAI stock, giving a Buy rating on November 14. Michael ...

Its product candidates include COMP360/Psilocybin therapy, PCN-101/R-ketamine, RL-007/Compound, DMX-1002/Ibogaine, GRX-917/Deuterated etifoxine, VLS-01/DMT, EMP-01/MDMA derivative, RLS-01 ...